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Abstract Peroxisome proliferator-activated receptor Q (PPARQ)
plays a central role in adipocyte di¡erentiation and insulin sen-
sitivity. Although PPARQ also appears to regulate diverse cel-
lular processes in other cell types such as lymphocytes, the de-
tailed mechanisms remain unclear. In this study, we established
a lentivirus-mediated short hairpin RNA expression system and
identi¢ed a potent short hairpin RNA which suppresses PPARQ
expression, resulting in marked inhibition of preadipocyte-to-
adipocyte di¡erentiation in 3T3-L1 cells. Our PPARQ-knock-
down method will serve to clarify the PPARQ pathway in var-
ious cell types in vivo and in vitro, and will facilitate the devel-
opment of therapeutic applications for a variety of diseases.
) 2004 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
The peroxisome proliferator-activated receptor (PPAR)
family was discovered as an orphan nuclear receptor, and
three di¡erent subtypes were subsequently identi¢ed, namely
PPARK, PPARN/L and PPARQ. PPARQ is abundantly ex-
pressed in adipose tissue and plays a key role in adipocyte
di¡erentiation and insulin sensitivity [1]. Recently, our group
and other researchers reported that PPARQ is also an attrac-
tive therapeutic target as it can play an important role in
immune responses, especially in transcriptional regulation of
in£ammatory responses [2^5].
The biological role of PPARQ had been widely investigated
by using PPARQ-de¢cient mice generated by targeted disrup-
tion of the PPARQ gene. Since homozygous PPARQ-de¢cient
mice (PPARQ3=3) are embryonic lethal due to placental dys-
function [1], heterozygous mice (PPARQþ=3) have been used
to investigate the role of PPARQ in vivo experiments. How-
ever, PPARQþ=3 mice seem to be of limited use in some ex-
periments, because PPARQ also appears to regulate diverse
cellular processes in cells that show lower levels of PPARQ
expression in comparison to adipose tissue [6,7].
RNA interference (RNAi) is a powerful technique for se-
lectively silencing the expression of genes. Recent work has
provided a system for the stable expression of short interfering
RNA (siRNA) in mammalian cells, which is generally based
on the expression of short hairpin RNA (shRNA) under the
control of the RNA polymerase III promoter [8^11]. The tech-
nique has allowed for the development of a new approach for
achieving targeted gene silencing of disease-associated genes in
animal models as well as in cultured cells.
Lentiviral vectors (LVs) are a promising tool for exogenous
gene transfer among gene transfer vehicles, because LVs have
the advantages of infecting non-dividing cells and being stably
integrated into the host genome resulting in long-term expres-
sion of transgene [12^16]. Furthermore, recent reports have
demonstrated that virus-mediated RNAi could provide long-
term silencing in mammalian cells [9,17,18]. In the present
study, we attempted to develop a technique for suppressing
the expression of PPARQ in vivo and in vitro. We established
a lentivirus-mediated shRNA expression system and identi¢ed
a potent shRNA target sequence in the coding region of
PPARQ mRNA. This approach has enabled us to clarify a
novel role of PPARQ.
2. Materials and methods
2.1. Vector construction
Vectors were constructed using standard cloning procedures. H1-
RNA promoter was ampli¢ed from human genomic DNA (Clontech,
Palo Alto, CA, USA) using the following primers: 5P-CCATG-
GAATTCGAACGCTGACGTC-3P and 5P-GCAAGCTTAGATCT-
GTGGTCTCATACAGAACTTATAAGATTCCC-3P. The ampli¢ed
polymerase chain reaction (PCR) product was inserted into the
EcoRI-BglII site of pHM5 [19], generating pHM5-H1. pHM5-H1
was designed to express shRNA upon the insertion of an appropriate
sequence into the BglII/XbaI site (Fig. 1A). Oligonucleotides encoding
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both strands of the targeting sequence were annealed and inserted into
BglII/XbaI sites of pHM5-H1 (Fig. 1A and Table 1). The sequence
was veri¢ed on a DNA sequencer (ABI Prism 310, Applied Biosys-
tems) and the cassette containing the H1 promoter plus the shRNA
was transferred to a self-inactivating (SIN) LV construct, generating
CS-H1-shRNA-EG (Fig. 1B).
2.2. Preparation of LV expressing shRNA (LV-shRNA)
LVs pseudotyped with vesicular stomatitis virus G glycoprotein
(VSV-G) were prepared according to a previously described method
[15,20,21]. Brie£y, 293T cells were transfected with four plasmids:
packaging construct (pMDLg/pRRE), VSV-G-expressing construct
(pMD.G), Rev-expressing construct (pRSV-Rev), and SIN vector
construct (CS-H1-shRNA-EG). Vector supernatant was concentrated
by ultracentrifugation, and the pellet was resuspended in Hanks’ bal-
anced salt solution. Vector titers, which can be detected by enhanced
green £uorescent protein (EGFP) expression under the control of a
human elongation factor 1K subunit gene promoter, were determined
by infection of HeLa P4 cells with serial dilutions of the vector stocks,
followed by £uorescence-activated cell sorter (FACS) analysis for
EGFP-positive cells.
2.3. Cell culture and infection of LV-shRNA
3T3-L1 preadipocytes were cultured in Dulbecco’s modi¢ed Eagle’s
medium supplemented with 10% fetal bovine serum. The 3T3-L1 cells
were infected with viral stocks at a multiplicity of infection (MOI) of
50 or 200, followed by FACS analysis for EGFP expression. Trans-
duction e⁄ciencies were 66.57%R1.44 at 50 MOI and 91.64%R1.07
at 200 MOI, expressed as S.E.M. The transduced 3T3-L1 cells were
grown and then used in subsequent experiments.
2.4. Di¡erentiation protocol
Induction of adipocyte di¡erentiation was performed essentially as
described [22]. Two days after con£uence (day 0), the medium was
replaced with di¡erentiation medium containing rosiglitazone (BRL,
1 WM), insulin (INS, 150 nM), dexamethasone (DEX, 1 WM) and 3-
isobutyl-1-methylxanthine (IBMX, 100 WM), which was changed every
3 days thereafter until analysis.
2.5. Measurement of adipocyte di¡erentiation
Di¡erentiation of 3T3-L1 preadipocytes to adipocytes was moni-
tored by measurement of intracellular lipid accumulation using Oil
red O staining and glycerol-3-phosphate dehydrogenase (GPDH) ac-
tivity on day 9. Cultured cells were ¢xed for 2 h with 10% formalin in
isotonic phosphate bu¡er and then washed with distilled water. The
cells were then stained by complete immersion in a working solution
(0.3%) of Oil red O for 4 h. Excess dye was removed by exhaustive
washing with water. The GPDH activity was measured using a GPDH
assay kit (Hokudo, Hokkaido, Japan).
2.6. RNA isolation and reverse transcription (RT) PCR analysis
Total RNA was extracted from the 3T3-L1 cells infected with each
kind of LV-shRNA using Tri-Reagent (Sigma). First-strand cDNA
was generated from 1 Wg of RNA by using oligo(dT1218) primer
(Invitrogen) and SuperScript III RNase H Reverse Transcriptase (In-
vitrogen) according to the manufacturer’s protocol. The reverse tran-
scription reaction mix was ampli¢ed with the following pair of oligo-
nucleotides speci¢c for murine PPARK, PPARN, PPARQ2 and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH): PPARK, 5P-
CGACAAGTGTGATCGGAGCTGCAAG-3P and 5P-GTTGAAGT-
TCTTCAGGTAGGCTTC-3P ; PPARN, 5P-GGCCAACGGCAGTG-
GCTTCGTC-3P and 5P-GGCTGCGGCCTTAGTACATGTCCT-3P ;
PPARQ2, 5P-GCTGTTATGGGTGAAACTCTG-3P and 5P-ATAA-
GGTGGAGATGCAGGTTC-3P ; GAPDH, 5P-GCTCACTGGCAT-
GGCCTTC-3P and 5P-ACCACCCTGTTGCTGTAGC-3P [23]. The
sample was ampli¢ed in the linear phase, optimized for each gene
(PPARK : 38 cycles; PPARN : 30 cycles; PPARQ2: 36 cycles;
GAPDH: 23 cycles). All PCR products were electrophoresed on 2%
agarose gel using 0.5UTris-borate-EDTA bu¡er and visualized using
ethidium bromide. The gel image was captured by a digital camera,
and densitometric analysis was performed using NIH Image software.
2.7. Western blot analysis
Cultured cells were homogenized in Tris^HCl bu¡er containing a
cocktail of protease inhibitors and insoluble materials were then re-
moved by centrifugation at 4‡C. The solubilized lysates were resolved
by sodium dodecyl sulfate^polyacrylamide gel electrophoresis under
reducing conditions at a concentration of 5 Wg protein of sample per
lane. Detection of PPARK, PPARN, PPARQ and GAPDH was respec-
tively performed with anti-PPARK polyclonal antibody (Santa Cruz
Biotechnology, Santa Cruz, CA, USA), anti-PPARN polyclonal anti-
body (Santa Cruz Biotechnology), anti-PPARQ monoclonal antibody
(Santa Cruz Biotechnology) and anti-GAPDH polyclonal antibody
(Trevigen, Gaithersburg, MD, USA) according to a previously de-
scribed method [4]. The band intensity was quanti¢ed using NIH
Image software.
2.8. Statistical analysis
All results are expressed as meanRS.E.M. Statistical comparisons
were made with Student’s t-test or Sche¡e¤’s method after analysis of
variances. The results were considered signi¢cantly di¡erent at
P6 0.05.
Fig. 1. Vector construction. A: pHM5-H1 was constructed as de-
scribed in Section 2. Oligonucleotides encoding both strands of the
targeting sequence, a spacer sequence which provided a loop struc-
ture and a transcriptional termination signal T5 were annealed and
inserted into BglII/XbaI sites in pHM5-H1. B: Schematic represen-
tation of self-inactivating (SIN) LV plasmid (CS-H1-shRNA-EG).
CMV: cytomegalovirus promoter, 8 : packaging signal, RRE: rev
responsive element, cPPT: central polypurine tract, H1: human H1
promoter, EF-1K : human elongation factor 1K subunit gene pro-
moter, EGFP: enhanced green £uorescent protein, WPRE: wood-
chuck hepatitis virus posttranscriptional regulatory element. v : de-
leting 133 bp in the U3 region of the 3P long terminal repeat.
Table 1
LV vectors used in this study
LV vector shRNA target
gene
shRNA target sequence
LV-shRNA-P11 PPARQ1 and 2 CAGCTCTACAACAGGCCTC
LV-shRNA-P12 PPARQ1 and 2 ATGGCCATTGAGTGCCGAG
LV-shRNA-P13 PPARQ1 and 2 TAAATGTCAGTACTGTCGG
LV-shRNA-P14 PPARQ1 and 2 TTGGCGGAGATCTCCAGTG
LV-shRNA-P15 PPARQ1 and 2 GTCTGCTGATCTGCGAGCC
LV-shRNA-P16 PPARQ1 and 2 TCACCATTTGTCATCTACG
LV-shRNA-P17 PPARQ1 and 2 GTTTGAGTTTGCTGTGAAG
LV-shRNA-P18 PPARQ1 and 2 ATGAGCCTTCACCCCCTGC
LV-shRNA-P19 PPARQ1 and 2 GATCTGCGAGCCCTGGCAA
LV-shRNA-P21 PPARQ2 ACTCTGGGAGATTCTCCTG
LV-shRNA-P22 PPARQ2 CCTTCGCTGATGCACTGCC
LV-shRNA-Lu Luciferase ACGCTGAGTACTTCGAAAT
LV-shRNA-Scramble No target gene GCGCGCTTTGTAGGATTCG
LV-EG ^ ^
LV-EG has no shRNA-expressing cassette. All vectors carry an
EGFP-expressing cassette as a marker gene so that the cells trans-
duced with LV-shRNAs can be identi¢ed by green £uorescence.
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3. Results and discussion
To develop an e¡ective PPARQ-knockdown method, we
constructed an LV-based siRNA system in which shRNA
encoding both strands of the targeting sequence is expressed
under the control of human H1 promoter [24]. A human H1
promoter was cloned to generate pHM5-H1, and oligonucleo-
tide encoding shRNA against PPARQ mRNA was inserted
(Fig. 1A). Subsequently, the cassette containing the H1 pro-
moter plus the shRNA was transferred to the SIN LV con-
struct (Fig. 1B). Using a shRNA target sequence against ¢re-
£y luciferase, we previously demonstrated that our LV-based
siRNA system e¡ectively suppressed the target gene in mam-
malian cells (data not shown).
PPARQ exists as two isoforms, termed PPARQ1 and PPARQ2,
which are produced by a combination of di¡erent promoters
and alternative splicing. PPARQ2 has an N-terminal extension
of 30 amino acids and is very highly expressed in adipocytes
[22,25]. We selected 11 target sequences in the coding region
of PPARQmRNA and constructed LV-shRNAs against PPARQ
(Table 1). In the present study, LV-shRNA-Lu, LV-shRNA-
Scramble and LV-EG were used as controls.
To ¢nd the most e¡ective shRNA target sequence against
PPARQ, we analyzed the silencing of PPARQ in 3T3-L1 cells
during preadipocyte-to-adipocyte di¡erentiation in which
PPARQ is known to be a master regulator of adipogenesis
[1,26,27]. The expression of PPARQ increases during the di¡er-
entiation process and activation of PPARQ protein by its li-
gand leads to adipogenesis through the activation of the adi-
pogenic gene cascade. The 3T3-L1 preadipocytes transduced
with each of the LV-shRNAs, i.e. 3T3-L1 cells expressing
shRNAs, as listed in Table 1, were exposed to di¡erentiation
medium (DM) 2 days after con£uence (day 0). Initially, silenc-
ing of PPARQ expression was examined by RT-PCR after 2
days of culture in DM (Fig. 2). Although 3T3-L1 cells trans-
duced with LV-shRNA-Lu, -Scramble and LV-EG showed
Fig. 2. Alteration of PPAR family mRNA levels in 3T3-L1 cells
transduced with LV-shRNAs. A: 3T3-L1 preadipocytes were in-
fected with each LV-shRNA (200 MOI) and then subjected to the
di¡erentiation protocol. Two days after the induction of adipocyte
di¡erentiation, mRNA levels of PPARQ2, PPARK, PPARN, and
GAPDH were determined by RT-PCR analysis. Results are repre-
sentative gel images. B: Densitometric quantitation for PPARQ and
GAPDH from three to four independent experiments. Each PPARQ
value was normalized to the values for GAPDH and expressed as
fold induction over the basal level detected in 3T3-L1 preadipocytes
(bars, S.E.M.). **P6 0.01 for LV-shRNA-P15 and -P17 compared
with LV-shRNA-Lu, LV-shRNA-Scramble or LV-EG.
Fig. 3. E¡ect of LV-shRNAs on adipocyte di¡erentiation. A: Di¡er-
entiation of 3T3-L1 preadipocytes (infected with LV-shRNA; 200
MOI) to adipocytes was monitored by measurement of intracellular
lipid accumulation using Oil red O staining on day 9. B: GPDH ac-
tivity was measured on day 9. Data were expressed as percentage of
the GPDH activity of 3T3-L1 cells which were infected with LV-
shRNA-Scramble (200 MOI). a: LV-shRNA-P11; b: LV-shRNA-
P12; c: LV-shRNA-P13; d: LV-shRNA-P14; e: LV-shRNA-P15; f:
LV-shRNA-P16; g: LV-shRNA-P17; h: LV-shRNA-P18; i : LV-
shRNA-P19; j : LV-shRNA-P21; k: LV-shRNA-P22; l : LV-EG; m:
LV-shRNA-Lu; n: LV-shRNA-Scramble. Similar results were ob-
tained in two independent experiments.
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signi¢cant increases in the levels of PPARQ mRNA, 3T3-L1
cells transduced with LV-shRNA-P15 and -P17 retained low
levels of PPARQ mRNA comparable to the level in preadipo-
cytes maintained in normal culture medium. In contrast, the
expression levels of GAPDH, PPARK and PPARN were not
altered by LV-shRNA-P15 or -P17. The other LV-shRNAs
against PPARQ caused moderate decreases in the levels of
PPARQ mRNA.
The di¡erentiation of 3T3-L1 preadipocytes to adipocytes
can be monitored by measurement of intracellular lipid accu-
mulation and GPDH (an important enzyme in triglyceride
synthesis) activity [28^30]. Intracellular lipid accumulation
was dramatically reduced in the LV-shRNA-P15- and -P17-
infected 3T3-L1 cells as shown by Oil red O staining (Fig. 3A,
e: LV-shRNA-P15; g: LV-shRNA-P17). GPDH activity also
demonstrated that LV-shRNA-P15 and LV-shRNA-P17 ex-
press a potent shRNA which suppresses PPARQ mRNA ex-
pression, resulting in marked inhibition of preadipocyte-to-
adipocyte di¡erentiation (Fig. 3B). We also con¢rmed that
the expression of PPARQ-inducible genes, such as uncoupling
protein-1 and adipocyte fatty acid binding protein, were in-
hibited in 3T3-L1 cells transduced with LV-shRNA-P15 and
LV-shRNA-P17 in the presence of the PPARQ-speci¢c ligand,
BRL (unpublished data).
A recent study demonstrated that if the degree of comple-
mentarity to its target is reduced, siRNA can function as
microRNAs which a¡ect translational suppression without
cleavage [31]. An important objective of this study was to
determine whether the silencing e¡ect of PPARQ caused by
these LV-shRNAs was speci¢c for PPARQ. In fact, several
shRNA target sequences used in this study partially corre-
spond to PPARK or PPARN. Western blotting analysis dem-
onstrated that PPARQ protein levels were signi¢cantly de-
creased in the LV-shRNA-P15- and LV-shRNA-P17-infected
3T3-L1 cells, while LV-shRNAs did not alter the amount of
PPARK, PPARN or GAPDH protein (Fig. 4). These results
were consistent with the result from RT-PCR analysis
(Fig. 2).
Furthermore, we examined 3T3-L1 cells exposed to either
LV-shRNA-Scramble, -P15 or -P17 by £uorescent microscopy
for EGFP expression to identify cells not infected with those
vectors, i.e. the 3T3-L1 cells not expressing the shRNA en-
coded by LV-shRNA-P15 or -P17 (Fig. 5). In the case of LV-
shRNA-Scramble, which expresses control shRNA, the di¡er-
entiation of preadipocytes to adipocytes was not a¡ected by
infection with LV. In contrast, all of the cells infected with
LV-shRNA-P15 or -P17 retained their ¢broblast-like mor-
phology. Taken together, these results indicate that our LV-
shRNA-based PPARQ-knockdown method resulted in de-
creased PPARQ expression and speci¢c inhibition of the PPARQ
pathway, even in the case of adipocyte di¡erentiation in which
PPARQ expression is strongly induced by DM and PPARQ
protein is e¡ectively activated by the PPARQ-speci¢c ligand
used in this study, BRL.
Accessibility of the siRNA might depend on the secondary
structure of the target mRNA. However, a clear correlation
between either secondary structure or GC content and e¡ec-
tiveness of target sites has not yet been recognized. Although
we designed 11 di¡erent shRNAs against PPARQ, we have not
found any correlation between several factors that have been
implicated in the accessibility of transcriptional/translational
regulatory elements and e¡ectiveness of target sites of shRNA
until now.
In the present study, we developed a promising tool for
suppressing the expression of PPARQ. Our PPARQ-knock-
down method will serve to clarify the role of the PPARQ
pathway in various cell types in vivo and in vitro, and will
facilitate the development of therapeutic applications for a
variety of diseases.
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Fig. 4. Alteration of PPAR family protein levels in 3T3-L1 cells
transduced with LV-shRNAs (200 MOI). A: Four days after the in-
duction of adipocyte di¡erentiation, the whole cell extract was ana-
lyzed by Western blotting with antibodies against PPARQ, PPARK,
PPARN and GAPDH. Results are representative of three individual
experiments. B: Densitometric quantitation for PPARQ and
GAPDH from three individual experiments. Each PPARQ value was
normalized to the values for GAPDH and expressed as fold induc-
tion over the basal level detected in 3T3-L1 preadipocytes (bars,
S.E.M.). **P6 0.01 for LV-shRNA-P13, -P15 and -P17 compared
with LV-shRNA-Scramble or LV-EG. *P6 0.05 for LV-shRNA-
P13 compared with LV-EG.
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Fig. 5. Identi¢cation of the 3T3-L1 cells transduced with LV-shRNA. Bright¢eld and £uorescent microscopy images collected from the same
¢eld. The LV-shRNA-infected cells, which expressed EGFP, were detected as green £uorescence (upper panels) and morphologically identi¢ed
mature adipocyte with a voluminous spherical shape and a large accumulation of intracytoplasmic lipid vesicles (lower panels). Bars represent
100 Wm.
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